Scarica l'app Stockscreener
59.99
4.52%
-2.84
Dopo l'orario di chiusura:
60.00
0.010
+0.02%
Precedente Chiudi:
$62.83
Aprire:
$62.99
Volume 24 ore:
2.20M
Relative Volume:
0.70
Capitalizzazione di mercato:
$3.29B
Reddito:
$14.34M
Utile/perdita netta:
$-199.00M
Rapporto P/E:
-15.30
EPS:
-3.92
Flusso di cassa netto:
$-183.51M
1 W Prestazione:
-5.75%
1M Prestazione:
+314.58%
6M Prestazione:
+538.87%
1 anno Prestazione:
+827.20%
Intervallo 1D:
$59.39
$65.14
Intervallo di 1 settimana:
$58.12
$65.14
Portata 52W:
$5.35
$65.14
Uniqure N V Stock (QURE) Company Profile
Nome
Uniqure N V
Settore
Industria
Telefono
1-339-970-7000
Indirizzo
PAASHEUVELWEG 25A, AMSTERDAM
Confronta QURE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
QURE
Uniqure N V
|
59.99 | 3.63B | 14.34M | -199.00M | -183.51M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-14 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2025-04-01 | Ripresa | Chardan Capital Markets | Buy |
| 2024-12-10 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-02-29 | Downgrade | Goldman | Buy → Neutral |
| 2023-12-19 | Downgrade | Mizuho | Buy → Neutral |
| 2022-03-17 | Aggiornamento | UBS | Neutral → Buy |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-05-21 | Iniziato | UBS | Neutral |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-04-01 | Aggiornamento | Mizuho | Neutral → Buy |
| 2021-01-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-11-24 | Iniziato | H.C. Wainwright | Buy |
| 2020-11-11 | Iniziato | Berenberg | Buy |
| 2020-11-09 | Iniziato | Jefferies | Buy |
| 2020-11-04 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-10-23 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-08-25 | Iniziato | Raymond James | Strong Buy |
| 2020-07-31 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2020-06-25 | Downgrade | Mizuho | Buy → Neutral |
| 2020-06-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-06-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2019-12-03 | Iniziato | Cowen | Outperform |
| 2019-12-03 | Iniziato | Goldman | Buy |
| 2019-11-05 | Iniziato | Credit Suisse | Outperform |
| 2019-10-11 | Iniziato | Stifel | Buy |
| 2019-09-25 | Iniziato | Bernstein | Outperform |
| 2019-09-12 | Iniziato | Mizuho | Buy |
| 2019-07-30 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-07-08 | Reiterato | Cantor Fitzgerald | Overweight |
| 2019-04-12 | Iniziato | Piper Jaffray | Overweight |
| 2019-03-29 | Iniziato | Robert W. Baird | Outperform |
Mostra tutto
Uniqure N V Borsa (QURE) Ultime notizie
Is uniQure N.V. stock trading at a premium valuation2025 Top Decliners & Low Risk Growth Stock Ideas - newser.com
How institutional buying supports uniQure N.V. stockMarket Activity Summary & Accurate Entry/Exit Alerts - newser.com
uniQure (QURE) Short Interest and Buy Rating Attract Investor Attention - GuruFocus
uniQure N.V. (QURE) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
uniQure N.V. stock outlook for YEARTrend Reversal & Expert Verified Stock Movement Alerts - newser.com
Using Bollinger Bands to evaluate uniQure N.V.2025 Market Outlook & Expert Curated Trade Setups - newser.com
Can uniQure N.V. stock hit analyst price targetsLong Setup & Risk Controlled Swing Alerts - newser.com
Is uniQure N.V. stock a safe investment in uncertain marketsJuly 2025 Update & Low Drawdown Trading Techniques - newser.com
What catalysts could drive uniQure N.V. stock higher2025 Top Decliners & Technical Pattern Recognition Alerts - newser.com
uniQure N.V. $QURE Shares Purchased by Aberdeen Group plc - MarketBeat
uniQure NV Hits New 52-Week High of $61.79, Surging 1014.68% - Markets Mojo
uniQure N.V. (NASDAQ:QURE) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Is uniQure’s Rally Justified After Positive Huntington’s Disease Therapy Data? - Yahoo Finance
Jim Cramer on uniQure: “This One Has Too Many Questions for Me Up Here” - MSN
Trend analysis for uniQure N.V. this week2025 Momentum Check & Expert Verified Movement Alerts - newser.com
Will uniQure N.V. see short term momentumBreakout Watch & Verified Technical Trade Signals - newser.com
uniQure N.V. (QURE) Stock Report: A Look at Strong Buy Ratings Amidst Clinical Advancements - DirectorsTalk Interviews
Will uniQure N.V. (UQ1) stock beat value stocksDay Trade & AI Powered Market Trend Analysis - newser.com
Weiss Ratings Reaffirms "Sell (D-)" Rating for uniQure (NASDAQ:QURE) - MarketBeat
Is uniQure’s Stock Poised for a Comeback? - StocksToTrade
Price momentum metrics for uniQure N.V. explainedBreakout Watch & Technical Entry and Exit Tips - newser.com
Developing predictive dashboards with uniQure N.V. dataWeekly Trade Report & Verified Stock Trade Ideas - newser.com
Biopharma Financing Veers Toward Optimism, But Cell And Gene Therapies Left Behind - insights.citeline.com
uniQure: Further Upside Likely As The Opportunity Becomes Better Understood (QURE) - Seeking Alpha
uniQure NV Hits Day High with 9.47% Surge Amid Strong Intraday Performance - Markets Mojo
uniQure (NASDAQ:QURE) Sets New 12-Month HighTime to Buy? - MarketBeat
Uniqure NV stock hits 52-week high at 60.84 USD By Investing.com - Investing.com Nigeria
RBC Capital Maintains UniQure NV(QURE.US) With Buy Rating, Raises Target Price to $65 - 富途牛牛
Uniqure NV stock hits 52-week high at 60.84 USD - Investing.com
United States Adeno-Associated Virus (AAV) Vectors - openPR.com
HC Wainwright Analysts Lift Earnings Estimates for uniQure - MarketBeat
UniQure’s Unexpected Surge: Analyzing QURE’s Performance - timothysykes.com
uniQure (NASDAQ:QURE) Shares Up 7.7% Following Analyst Upgrade - MarketBeat
HC Wainwright Issues Positive Forecast for uniQure Earnings - MarketBeat
uniQure’s Huntington’s gene therapy holds blockbuster potential, says analyst - The Pharma Letter
Uniqure N V Azioni (QURE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Uniqure N V Azioni (QURE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Kapusta Matthew C | CEO, Managing Director |
Sep 24 '25 |
Sale |
41.46 |
226,316 |
9,382,473 |
651,454 |
| KLEMT CHRISTIAN | Chief Financial Officer |
Sep 26 '25 |
Option Exercise |
5.37 |
15,000 |
80,550 |
232,730 |
| KLEMT CHRISTIAN | Chief Financial Officer |
Sep 24 '25 |
Option Exercise |
13.03 |
3,000 |
39,090 |
220,730 |
| KLEMT CHRISTIAN | Chief Financial Officer |
Sep 26 '25 |
Sale |
55.00 |
15,000 |
825,000 |
217,730 |
| KLEMT CHRISTIAN | Chief Financial Officer |
Sep 24 '25 |
Sale |
40.04 |
3,000 |
120,120 |
217,730 |
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):